Acceleron Pharma Company Profile (NASDAQ:XLRN)

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XLRN
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.34392 billion
  • Outstanding Shares: 38,685,000
Average Prices:
  • 50 Day Moving Avg: $32.45
  • 200 Day Moving Avg: $29.10
  • 52 Week Range: $23.07 - $41.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.25
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $13.14 million
  • Price / Sales: 102.57
  • Book Value: $4.88 per share
  • Price / Book: 7.14
  • EBIDTA: ($96,080,000.00)
  • Net Margins: -724.22%
  • Return on Equity: -44.67%
  • Return on Assets: -40.14%
  • Current Ratio: 10.39%
  • Quick Ratio: 10.39%
  • Average Volume: 350,381 shs.
  • Beta: 1.72
  • Short Ratio: 9.74
Frequently Asked Questions for Acceleron Pharma (NASDAQ:XLRN)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.12. The firm earned $3.10 million during the quarter, compared to analysts' expectations of $3.69 million. Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. Acceleron Pharma's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.59) EPS. View Acceleron Pharma's Earnings History.

When will Acceleron Pharma make its next earnings announcement?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Acceleron Pharma.

Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?

15 analysts have issued 12-month price objectives for Acceleron Pharma's stock. Their predictions range from $20.00 to $63.00. On average, they expect Acceleron Pharma's stock price to reach $42.31 in the next twelve months. View Analyst Ratings for Acceleron Pharma.

What are analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

  • 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)
  • 2. Cann analysts commented, "Acceleron Pharma announced today that updated preliminary results from phase II studies of Luspatercept in beta-thalassemia were released at the 22nd Congress of the European Hematology Association. It was reported that results from this ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment. These data presented today are very encouraging and appear to be as good as or better than data previously presented for Luspatercept." (6/23/2017)
  • 3. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:

  • Francois E. Nader M.D., Independent Chairman of the Board
  • Habib J. Dable, President, Chief Executive Officer, Director
  • Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer
  • Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer
  • Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer
  • John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary
  • Jean M. George, Independent Director
  • George S. Golumbeski Ph.D., Independent Director
  • Terrence C. Kearney, Independent Director
  • Tom Maniatis Ph.D., Independent Director

Who owns Acceleron Pharma stock?

Acceleron Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (12.25%), BlackRock Inc. (10.37%), Vanguard Group Inc. (5.25%), Westfield Capital Management Co. LP (4.36%), Eagle Asset Management Inc. (3.25%) and State Street Corp (2.93%). Company insiders that own Acceleron Pharma stock include Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Who sold Acceleron Pharma stock? Who is selling Acceleron Pharma stock?

Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Candriam Luxembourg S.C.A., Sphera Funds Management LTD., Marshall Wace North America L.P., Wells Fargo & Company MN, Franklin Resources Inc., Century Capital Management LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Acceleron Pharma stock in the last year include Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Insider Buying and Selling for Acceleron Pharma.

Who bought Acceleron Pharma stock? Who is buying Acceleron Pharma stock?

Acceleron Pharma's stock was bought by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Sectoral Asset Management Inc, BlackRock Inc., AXA, UBS Asset Management Americas Inc., First Manhattan Co., Vanguard Group Inc. and State Street Corp. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy Acceleron Pharma stock?

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of Acceleron Pharma stock can currently be purchased for approximately $34.84.

MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $42.31 (21.43% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/5/2017Credit Suisse GroupSet Price TargetBuy$35.00LowView Rating Details
8/4/2017Citigroup Inc.Boost Price TargetBuy$44.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingBuy$40.00MediumView Rating Details
6/23/2017CannReiterated RatingNeutral -> HoldHighView Rating Details
6/14/2017InstinetReiterated RatingBuy$58.00LowView Rating Details
6/13/2017FBR & CoSet Price TargetBuy$63.00HighView Rating Details
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 -> $42.00HighView Rating Details
6/13/2017CIBCDowngradeOutperform -> Market PerformLowView Rating Details
6/13/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform -> Market PerformHighView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Initiated CoverageSell -> Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
3/14/2017J P Morgan Chase & CoInitiated CoverageNeutral -> Neutral$33.00HighView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
6/13/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $42.00N/AView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00N/AView Rating Details
(Data available from 8/16/2015 forward)


Earnings History for Acceleron Pharma (NASDAQ:XLRN)
Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Earnings History by Quarter for Acceleron Pharma (NASDAQ XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.65)($0.77)$3.69 million$3.10 millionViewListenView Earnings Details
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
2017 EPS Consensus Estimate: ($2.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.62)($0.51)($0.57)
Q2 20173($0.69)($0.62)($0.66)
Q3 20173($0.71)($0.54)($0.64)
Q4 20173($0.75)($0.53)($0.66)
(Data provided by Zacks Investment Research)


Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acceleron Pharma (NASDAQ:XLRN)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 83.41%
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017Ravindra KumarSVPSell13,065$35.41$462,631.65View SEC Filing  
7/5/2017Kevin F MclaughlinCFOSell34,400$32.00$1,100,800.00View SEC Filing  
7/5/2017Matthew L ShermanEVPSell16,000$32.00$512,000.00View SEC Filing  
7/5/2017Ravindra KumarSVPSell937$32.00$29,984.00View SEC Filing  
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.00View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.00View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.00View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.88View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.12View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.60View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.32View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acceleron Pharma (NASDAQ:XLRN)
Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
DateHeadline logo Brokerages Expect Acceleron Pharma Inc. (NASDAQ:XLRN) Will Post Quarterly Sales of $3.45 Million - August 12 at 10:16 AM logoLuspatercept: Opportunity for Celgene’s Long-Term Growth? - August 11 at 9:12 AM logoRavindra Kumar Sells 13,065 Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) Stock - August 9 at 8:22 PM logoAcceleron Pharma Inc. (XLRN) Price Target Raised to $44.00 at Citigroup Inc. - August 7 at 12:20 AM logoCredit Suisse Group Analysts Give Acceleron Pharma Inc. (XLRN) a $35.00 Price Target - August 6 at 8:56 AM logoAcceleron Pharma Inc. (XLRN) Upgraded by BidaskClub to Strong-Buy - August 6 at 8:42 AM logoAcceleron Pharma Reports Second Quarter 2017 Operational and Financial Results - August 4 at 10:13 AM logoEdited Transcript of XLRN earnings conference call or presentation 3-Aug-17 9:00pm GMT - August 4 at 10:13 AM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Announces Quarterly Earnings Results - August 3 at 7:26 PM logoAcceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease - August 1 at 7:59 AM logoAcceleron Pharma Inc. (XLRN) Downgraded by BidaskClub to "Buy" - July 31 at 8:38 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Receives Average Rating of "Buy" from Analysts - July 29 at 10:39 AM logoAcceleron Pharma's (NASDAQ:XLRN) "Buy" Rating Reiterated at Piper Jaffray Companies - July 28 at 7:53 AM logoAcceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017 - July 27 at 9:46 AM logoAcceleron Pharma Inc. (XLRN) Set to Announce Earnings on Wednesday - July 26 at 7:10 AM logoZacks: Brokerages Anticipate Acceleron Pharma Inc. (NASDAQ:XLRN) to Announce -$0.66 Earnings Per Share - July 21 at 9:48 AM logoAcceleron Pharma Inc. (XLRN) Upgraded to Buy by Zacks Investment Research - July 13 at 1:04 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN) SVP Sells $29,984.00 in Stock - July 7 at 9:02 PM logoAcceleron Pharma Inc. (XLRN) EVP Sells $512,000.00 in Stock - July 7 at 8:16 PM logoAcceleron Pharma Inc. (XLRN) CFO Sells $1,100,800.00 in Stock - July 7 at 7:57 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Receives Consensus Recommendation of "Buy" from Brokerages - July 4 at 11:06 AM logoZacks: Analysts Anticipate Acceleron Pharma Inc. (XLRN) Will Announce Quarterly Sales of $3.52 Million - June 28 at 9:51 AM logoAcceleron Pharma Inc. (XLRN) Expected to Post Earnings of -$0.66 Per Share - June 27 at 12:38 AM logoAcceleron Pharma Inc. (XLRN) Price Target Increased to $40.00 by Analysts at Piper Jaffray Companies - June 26 at 12:52 PM logoAcceleron Pharma (XLRN) Presents Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia - June 23 at 8:21 PM logoAcceleron Pharma Inc. (XLRN) Given "Hold" Rating at Cann - June 23 at 11:34 AM logoAcceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association - June 23 at 6:06 AM logoAcceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association - June 23 at 6:06 AM logoAcceleron Pharma Inc. (XLRN) Upgraded to "Buy" at BidaskClub - June 21 at 3:10 PM logoAcceleron Pharma Inc. (XLRN) Downgraded to Market Perform at CIBC - June 18 at 4:58 PM logoAcceleron Pharma Inc. (XLRN) Price Target Cut to $42.00 by Analysts at Morgan Stanley - June 18 at 4:20 PM logoAcceleron Pharma Inc. (XLRN) Given a $63.00 Price Target at FBR & Co - June 18 at 3:02 PM logoBiotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug - June 15 at 4:12 PM logoOppenheimer Holdings Weighs in on Acceleron Pharma Inc.'s Q2 2017 Earnings (XLRN) - June 15 at 7:38 AM logoAcceleron (XLRN) Kidney Cancer Candidate Fails in Phase II - June 14 at 4:17 PM logoAcceleron Pharma Inc. (XLRN) Receives "Buy" Rating from Instinet - June 14 at 9:44 AM logoAcceleron: When Bad News Is Really Good News - June 14 at 2:23 AM logoAcceleron investors react to trial flop with a shrug, then cheers - June 14 at 2:23 AM logoCan This Small Biotech Be Saved By Developing Anemia Drug? - June 14 at 2:23 AM logoOppenheimer Holdings, Inc. Reiterates Market Perform Rating for Acceleron Pharma Inc. (XLRN) - June 13 at 9:04 AM logoAcceleron Pharma (XLRN) Says DART Phase 2 Study of Dalantercept in RCC Didn't Met Primary Endpoint - June 12 at 8:12 PM logoAcceleron Pharma Inc. (XLRN) Is Falling After Phase 2 Study Failed - June 12 at 8:12 PM logoAcceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma - June 12 at 8:12 PM logoAcceleron Pharma Inc (XLRN) Receives Average Recommendation of "Buy" from Brokerages - June 9 at 10:58 AM logoAcceleron Pharma (XLRN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 9 at 2:48 AM logoETFs with exposure to Acceleron Pharma, Inc. : June 5, 2017 - June 6 at 2:54 AM logoAcceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : June 5, 2017 - June 5 at 9:35 AM logo$3.52 Million in Sales Expected for Acceleron Pharma Inc (XLRN) This Quarter - June 2 at 11:40 AM logoCann Reaffirms "Buy" Rating for Acceleron Pharma Inc (XLRN) - June 1 at 11:10 AM logo-$0.66 Earnings Per Share Expected for Acceleron Pharma Inc (XLRN) This Quarter - May 31 at 10:30 PM



Acceleron Pharma (XLRN) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by Staff